Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.10.15.21264977: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: The study was approved by the Norwegian, South-Eastern Regional Ethical Committee (Ref. Nr. 200631) and the Norwegian Medicines Agency (EudraCT Number: 2021-003618-37).
IRB: The study was approved by the Norwegian, South-Eastern Regional Ethical Committee (Ref. Nr. 200631) and the Norwegian Medicines Agency (EudraCT Number: 2021-003618-37).
Consent: All participants gave written, informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Correlations were assessed by Spearman p. Statistical analysis was conducted using SPSS® version 26 (SPSS … SciScore for 10.1101/2021.10.15.21264977: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: The study was approved by the Norwegian, South-Eastern Regional Ethical Committee (Ref. Nr. 200631) and the Norwegian Medicines Agency (EudraCT Number: 2021-003618-37).
IRB: The study was approved by the Norwegian, South-Eastern Regional Ethical Committee (Ref. Nr. 200631) and the Norwegian Medicines Agency (EudraCT Number: 2021-003618-37).
Consent: All participants gave written, informed consent.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Correlations were assessed by Spearman p. Statistical analysis was conducted using SPSS® version 26 (SPSS Inc., Chicago, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-